Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM-PAIN-001
- Development stage
- Unknown
- Lead developer
- VivaMed
- Modality
- Small Molecules
01
Overview
VM-PAIN-001 is a modified-release small molecule drug candidate being developed by VivaMed BioPharma for the treatment of Complex Regional Pain Syndrome (CRPS). Currently in Phase 2 clinical development, the drug utilizes a modified-release formulation to potentially optimize its therapeutic window and provide sustained pain relief for patients suffering from this chronic neuroinflammatory condition. While the specific molecular target has not been publicly disclosed by the developer, VM-PAIN-001 represents a key part of VivaMed's pain management pipeline, which also includes other candidates for neuropathic and postoperative pain.
Beyond the preview
Go deeper on VM-PAIN-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VM-PAIN-001.